XenoPort, Inc. (Nasdaq:XNPT) and the National Institute on Alcohol Abuse
and Alcoholism (NIAAA) announced today that they have entered into an
agreement to conduct a clinical trial of HORIZANT ®
(gabapentin enacarbil) Extended-Release Tablets as a potential treatment
for alcohol use disorder (AUD). Under the terms of the agreement,
XenoPort will supply clinical trial material and the NIAAA will conduct
and pay all other expenses associated with the proposed clinical trial
NRG Energy has entered into an agreement to purchase FCE's previously announced 1.4 megawatt fuel cell power plant project at University of Bridgeport NRG Energy will acquire long-term power purchase agreement for clean and efficient distributed power generation with predictable cash flows
DANBURY, Conn., Sept.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced it
has expanded its global license agreement with CURx Pharmaceuticals,
Inc. to also include the development and commercialization of Ligand’s
Captisol-enabled™ Lamotrigine program.
NETGEAR®, Inc. (NASDAQ:NTGR) ( www.netgear.com ),
a global networking company that delivers innovative products to service
providers, consumers, and businesses, will exhibit an expanded portfolio
of LTE products at the IBC trade show in Amsterdam from September 12
through September 16.
TransForce to Redeem 5.65% Convertible Unsecured Subordinated Debentures Canada NewsWire
TransForce Inc. is a North American leader in the transportation and
logistics industry, operating across Canada and the United States
through its subsidiaries.
Mandalay Resources and West Face Capital Inc. Announce Closing of Secondary Offering of Common Shares and Exercise in Full of Over-allotment Option Canada NewsWire
/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE
UNITED STATES ./ TORONTO , Sept.
By Inti Landauro
PARIS--French utility GDF Suez (GSZ.FR) Tuesday denied it ever abused its dominant position on the French gas market after the country's antitrust watchdog said it had found evidence against the company.
Senesco Technologies, Inc. (OTCQB:SNTI) (the “Company” or “Sevion”), a
clinical-stage company which discovers, develops and acquires
next-generation biologics for the treatment of cancer and immunological
diseases, announced today a corporate rebranding under which the Company
will change its name to Sevion
Therapeutics, Inc. The
Company will continue to trade as SNTI until a new ticker symbol is
Freescale Semiconductor (NYSE: FSL) today announced new VortiQa
L1 baseband software for TDD-LTE on the QorIQ
Qonverge BSC913x family of base station system-on-chip (SoC)
solutions, enabling OEMs and ODMs to rapidly deliver small cell
solutions to the evolving TDD-LTE market.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.